Cited by 174Cardiac electrophysiology and arrhythmiasCardiac Health and Mental HealthTreatment of Major Depression

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

A Comparison of the Risk of QT Prolongation Among SSRIs

Funk, Kylee A., Bostwick, Jolene R.·2013·Annals of Pharmacotherapy

DOI 10.1177/1060028013501994

Open this paper in CoChat — free account

Abstract

Objective : To report QT prolongation potential in selective serotonin reuptake inhibitors (SSRIs) in order to advise clinicians on safe use of SSRIs other than citalopram in light of citalopram warnings. Data Sources : Primary literature and case reports were identified through a systematic search. Data from drug manufacturers, package inserts, and the ArizonaCERT database were also utilized. Study Selection and Data Extraction : English-language studies and case reports were included. Data Synthesis : Studies demonstrate possible dose-related clinically significant QT prolongation with escitalopram. Fluoxetine, fluvoxamine, and sertraline at traditional doses demonstrate a lack of clinically significant increases in QTc in the majority of studies. Further, paroxetine monotherapy shows a lack of clinically significant QTc prolongation in all studies. However, case reports or reporting tools still link these SSRIs with QTc prolongation. Fluoxetine, escitalopram, and sertraline used in post–acute coronary syndrome patients did not demonstrate risk of QTc prolongation. Conclusion : For clinicians who choose not to use citalopram due to recent Food and Drug Administration (FDA) recommendations, other antidepressants within this class may be considered. When citalopram is not utilized based on risk factors for TdP, use of escitalopram is not likely the safest alternative. Based on current literature, fluoxetine, fluvoxamine, and sertraline appear to have similar, low risk for QT prolongation, and paroxetine appears to have the lowest risk. However, there are significant limitations in interpreting the studies, including varying definitions of significant QT prolongation. Therefore, choice of an alternative SSRI should be based on individual risk factors for arrhythmias and other patient-specific factors.

Integrity signals

Registry

Crossref · 10.1177/1060028013501994

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Pharmacotherapy: A Pathophysiologic Approach
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-5-447_3 · Cited by 2,402
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 821
What Clinicians Should Know About the QT Interval
Al‐Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., & Califf, R. M. (2003) · JAMA · doi:10.1001/jama.289.16.2120 · Cited by 671
Relative Toxicity of Selective Serotonin Reuptake Inhibitors (SSRIs) in Overdose
Isbister, G. K., Bowe, S. J., Dawson, A. H., & Whyte, I. M. (2004) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-120037428 · Cited by 432
QT interval and antidepressant use: a cross sectional study of electronic health records
Castro, V. M., Clements, C. C., Murphy, S. N., Gainer, V. S., D, M. F. M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., Iosifescu, D. V., et al. (2013) · BMJ · doi:10.1136/bmj.f288 · Cited by 316
Citalopram, QTc Interval Prolongation, and Torsade de Pointes. How Should We Apply the Recent FDA Ruling?
Vieweg, W. V. R., Hasnain, M., Howland, R. H., Hettema, J. M., Kogut, C., Wood, M. A., & Pandurangi, A. K. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.002 · Cited by 268
Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial
Strik, J. J. M. H., Honig, A., Lousberg, R. L., Lousberg, A., Cheriex, E. C., Tuynman-Qua, H. G., Kuijpers, P. M. J. C., Wellens, H. J. J., & van Praag, H. M. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200011000-00007 · Cited by 255
Cardiovascular Effects of Fluoxetine in Depressed Patients With Heart Disease
Roose, S. P., Glassman, A. H., Attia, E., Woodring, S., Giardina, E. V., & Bigger, J. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.660 · Cited by 212
Drug‐induced long QT syndrome: hERG K+channel block and disruption of protein trafficking by fluoxetine and norfluoxetine
Rajamani, S., Eckhardt, L. L., Valdivia, C. R., Klemens, C. A., Gillman, B. M., Anderson, C. L., Holzem, K. M., Delisle, B. P., Anson, B. D., Makielski, J. C., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706892 · Cited by 193

Show all 52 references

Research works printed but not linked: 2

Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: a critical analysis. J Clin Psychiatry. 1990;51(suppl B):37-39.
10.1345/aph.16185. · DOI · Paper page

Sorted by citations

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J. K., Bishop, J., Sangkuhl, K., Dj, M., Ji, Y., Leckband, S. G., Leeder, J. S., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 1,001
The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2903 · Cited by 521
Symptom burden in heart failure: assessment, impact on outcomes, and management
Alpert, C. M., Smith, M. A., Hummel, S. L., & Hummel, E. K. (2017) · Heart Failure Reviews · doi:10.1007/s10741-016-9581-4 · Cited by 304
Anxiety in Patients with Schizophrenia: Epidemiology and Management
Temmingh, H., & Stein, D. J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0282-7 · Cited by 173
Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Cubeddu, L. X. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160301120217 · Cited by 147
Antidepressant Drugs Effects on Blood Pressure
Calvi, A., Fischetti, I., Verzicco, I., Murri, M. B., Zanetidou, S., Volpi, R., Coghi, P., Tedeschi, S., Amore, M., & Cabassi, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.704281 · Cited by 153
Prevention of depression in older age
Almeida, O. P. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.03.005 · Cited by 132
Cognitive Impairment Evaluation and Management
McCollum, L., & Karlawish, J. H. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.06.007 · Cited by 114
2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 114
Risk of QT/QTc Prolongation Among Newer Non-SSRI Antidepressants
Jasiak, N. M., & Bostwick, J. R. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014550645 · Cited by 97
Self-citation
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., et al. (2023) · Focus · doi:10.1176/appi.focus.23021011 · Cited by 93
An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes
Mostafa, S., Kirkpatrick, C. M. J., Byron, K. A., & Sheffield, L. J. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1922-0 · Cited by 90
Treatment of Depression in Patients with Concomitant Cardiac Disease
Teply, R. M., Packard, K. A., White, N. D., Hilleman, D. E., & DiNicolantonio, J. J. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.11.003 · Cited by 78
Treatment-Resistant Depression in Older Adults
Steffens, D. C. (2024) · New England Journal of Medicine · doi:10.1056/nejmcp2305428 · Cited by 80
Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis
Assimon, M. M., Brookhart, M. A., & Flythe, J. E. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018101032 · Cited by 69
A comparative study of QT prolongation with serotonin reuptake inhibitors
Ojero-Senard, A., Bénévent, J., Bondon-Guitton, E., Durrieu, G., Chebane, L., Araujo, M., Montastruc, F., & Montastruc, J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4685-7 · Cited by 58
Antidepressants and the adolescent brain
Cousins, L., & Goodyer, I. M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573542 · Cited by 61
Update on long QT syndrome
Neira, V., Enriquez, A. A., Simpson, C., & Baranchuk, A. M. (2019) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14227 · Cited by 51
Understanding Mental Health Challenges in Cardiovascular Care
Borkowski, P., & Borkowska, N. (2024) · Cureus · doi:10.7759/cureus.54402 · Cited by 45
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
Eap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M., de León, J., Greiner, C., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1878427 · Cited by 51
Citalopram, QTc Prolongation, and Torsades de Pointes
Tampi, R. R., Balderas, M., Carter, K. V., Tampi, D. J., Moca, M., Knudsen, A., & May, J. T. (2014) · Psychosomatics · doi:10.1016/j.psym.2014.09.002 · Cited by 45
A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers
Kim, A., Lim, K. S., Lee, H., Chung, H., Yoon, S. H., Yu, K.-S., Cho, J., Jang, I., & Chung, J. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000124 · Cited by 42
Psychological and Psychopharmacological Interventions in Psychocardiology
Kahl, K. G., Stapel, B., & Correll, C. U. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.831359 · Cited by 40
Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
Mahdi, M., Hermán, L., Réthelyi, J., & Bálint, B. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073812 · Cited by 35
Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes
Pfeiffer, E. R., Vega, R., McDonough, P. M., Price, J. H., & Whittaker, R. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.04.007 · Cited by 34
Value of Supportive Care Pharmacogenomics in Oncology Practice
Patel, J. N., Wiebe, L. A., Dunnenberger, H. M., & McLeod, H. L. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0599 · Cited by 33
Using Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Critical Care: A Systematic Review of the Evidence for Benefit or Harm*
Kelly, J., Rubenfeld, G. D., Masson, N., Min, A., & Adhikari, N. K. J. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002308 · Cited by 32
Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations
Edinoff, A. N., Fort, J. M., Woo, J. J., Causey, C. D., Burroughs, C. R., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13030044 · Cited by 35
Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder
Shelton, R. C., Parikh, S. V., Law, R. A., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Macaluso, M., et al. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113017 · Cited by 31
Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study
Qirjazi, E., McArthur, E., Nash, D., Dixon, S., Weir, M., Vasudev, A., Jandoc, R., Gula, L., Oliver, M., Wald, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160768 · Cited by 31
Effect of Abrupt Discontinuation of Antidepressants in Critically Ill Hospitalized Adults
Bainum, T. B., Fike, D. S., Mechelay, D., & Haase, K. K. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1992 · Cited by 28
Antidepressant Effects of Essential Oils: A Review of the Past Decade (2012–2022) and Molecular Docking Study of Their Major Chemical Components
Fonseca, E. C. M., Ferreira, L. R., Figueiredo, P. L. B., Maia, C. D. S. F., Setzer, W. N., & da Silva, J. K. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119244 · Cited by 34
Effects of psychopharmacological treatment with antidepressants on the vascular system
Kahl, K. G., Westhoff‐Bleck, M., & Krüger, T. H. C. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.07.004 · Cited by 25
Direct and indirect effects of psychopharmacological treatment on the cardiovascular system
Kahl, K. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0054 · Cited by 23
Serotonergic Regulation in Alzheimer’s Disease
Долгачева, Л. П., Зинченко, В. П., Nadeev, A. D., & Goncharov, N. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115218 · Cited by 21
Psychotherapeutic Agents in End‐Stage Renal Disease
Eyler, R. F., Unruh, M. L., Quinn, D. K., & Vilay, A. M. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12370 · Cited by 20
Novel MYH7 mutation associated with mild myopathy but life-threatening ventricular arrhythmias and noncompaction
Finsterer, J., Stöllberger, C., Brandau, O., Laccone, F. A., Bichler, K., & Laing, N. G. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.03.025 · Cited by 20
Evidence for cardiotoxicity associated with sertraline in rats
Ilgın, S., Kılıç, V., Baysal, M., Kılıç, G., Uçarcan, Ş., Dermenci, B., & Atlı, Ö. (2018) · Toxicology Research · doi:10.1039/c8tx00072g · Cited by 21
Unintended Consequences of Adjusting Citalopram Prescriptions Following the 2011 FDA Warning.
Gerlach, L., Kales, H., Maust, D. T., Chiang, C., Stano, C., Choe, H., & Zivin, K. (2017) · The American journal of geriatric psychiatry · doi:10.1016/j.jagp.2016.11.010 · Cited by 16
Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs
Eap, C. B. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.3/ceap · Cited by 22
Increase of Heart Rate and QTc by Amitriptyline, But Not by Venlafaxine, Is Correlated to Serum Concentration
Unterecker, S., Pfuhlmann, B., Kopf, J., Kittel‐Schneider, S., Reif, A., & Deckert, J. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000336 · Cited by 19
Associations of Antidepressants With Atrial Fibrillation and Ventricular Arrhythmias: A Systematic Review and Meta-Analysis
Cao, Y., Zhou, M., Guo, H., & Zhu, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.840452 · Cited by 18
iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity
Lee, T. Y. T., Coles, J. G., & Maynes, J. T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1308217 · Cited by 18
From Evidence to Practice: A Comprehensive Analysis of Side Effects in Synthetic Anti-Depressant Therapy
Pannu, A. S., & Goyal, R. K. (2024) · Current Drug Safety · doi:10.2174/0115748863301630240417071353 · Cited by 21
Unprescribed and unnoticed: Retrospective chart review of adverse events of interactions between antidepressants and over-the-counter drugs
Woroń, J., Chrobak, A. A., Ślęzak, D., & Siwek, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.965432 · Cited by 17
A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS
Tan, H., Yan, X., Chen, Y., Huang, G., Luo, L., Li, W., Lan, W., Chen, C., & Xi, X. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1363382 · Cited by 20
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study
Ricardo-Silgado, M. L., Singh, S., Cifuentes, L., Decker, P. A., Gonzalez‐Izundegui, D., Moyer, A. M., Hurtado, M. D., Camilleri, M., Bielinski, S. J., & Acosta, A. J. (2022) · BMC Medicine · doi:10.1186/s12916-022-02433-x · Cited by 15
Proton pump inhibitors may enhance the risk of citalopram‐ and escitalopram‐associated sudden cardiac death among patients receiving hemodialysis
Assimon, M. M., Pun, P. H., Al‐Khatib, S. M., Brookhart, M. A., Gaynes, B. N., Winkelmayer, W. C., & Flythe, J. E. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5428 · Cited by 15
Anxiety in Individuals with Cardiovascular Diseases
Jiang, W. (2022) · Heart and Mind · doi:10.4103/hm.hm_5_22 · Cited by 13
The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram
Bugden, S., & Friesen, K. J. (2015) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s91046 · Cited by 14
Comparative responses to 17 different antidepressants in major depressive disorder: Results from a 2‐year long‐term nation‐wide population‐based study emulating a randomized trial
Kessing, L. V., Ziersen, S. C., Andersen, F. M., Gerds, T. A., & Budtz–Jørgensen, E. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13673 · Cited by 13
Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews
Lappas, A. S., Polyzopoulou, Z. A., Christodoulou, G. N., Bozikas, V., & Samara, M. T. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230801144328 · Cited by 12
Behandlung der Depression bei koronarer Herzerkrankung
Agorastos, A., Lederbogen, F., & Otte, C. (2015) · Der Nervenarzt · doi:10.1007/s00115-014-4162-z · Cited by 12
Vomiting, electrolyte disturbance, and medications; the perfect storm for acquired long QT syndrome and cardiac arrest: a case report
Tiver, K. D., Dharmaprani, D., Quah, J. X., Lahiri, A., Waddell-Smith, K. E., & Ganesan, A. N. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-021-03204-7 · Cited by 12
End-of-life care in patients with advanced heart failure
Diamant, M. J., Keshmiri, H., & Toma, M. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000712 · Cited by 12
Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa
Steulet, A., Obura, B., Waitt, C. J., Laker, E. A. O., Nicol, M. R., & Cresswell, F. V. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16154 · Cited by 11
Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study
Fung, K. W., Baye, F. M., Kapusnik-Uner, J., & McDonald, C. J. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00230-1 · Cited by 14
Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs
Chastang, A., Renet, S., Corny, J., Beaussier, H., Petre, A., Louët, A. L., Thi, T. T. P., & Bézie, Y. (2019) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0724-7 · Cited by 11
Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors
Bermel, R. A., Hashmonay, R., Meng, X., Randhawa, S., von Rosenstiel, P., Sfikas, N., & Kantor, D. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.04.002 · Cited by 12
Depression and anxiety disorders in chronic obstructive pulmonary disease patients: Prevalence, disease impact, treatment
Qiu, C., & Wu, S. (2024) · World Journal of Psychiatry · doi:10.5498/wjp.v14.i12.1797 · Cited by 10
The Antidepressant Paroxetine Reduces the Cardiac Sodium Current
Plijter, I. S., Verkerk, A. O., & Wilders, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031904 · Cited by 10
Opioid Deaths: Trends, Biomarkers, and Potential Drug Interactions Revealed by Decision Tree Analyses
Saad, M. H., Savonen, C., Rumschlag, M., Todi, S. V., Schmidt, C. J., & Bannon, M. J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00728 · Cited by 10
Mood Disorders and Addiction
Torrens, M., & Rossi, P. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-45375-5_8 · Cited by 10
Role of Pharmacokinetics and Pharmacogenetics of Antidepressant-Induced Prolongation of the QT Interval and Torsade de Pointes in Patients with Mental Disorders
Shnayder, N. A., Kidyaeva, A. V., Vaiman, E. E., Asadullin, A. R., Петрова, М. М., Kaskaeva, D. S., Matyushin, G. V., Evsyukov, A. A., Galko, E. V., Garganeeva, N. P., et al. (2023) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2023-3-2-72-119 · Cited by 11
Regulatory post‐market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies
Hooimeyer, A., Bhasale, A. L., Perry, L. T., Fabbri, A., Mohammad, A., McEwin, E. J., & Mintzes, B. J. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.680 · Cited by 9
Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis
Ramasubbu, S. K., Mishra, A., & Mandal, S. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221121371 · Cited by 11
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
Zhao, Y., Zhang, Y., Yang, L., Zhang, K., & Li, S. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241231116 · Cited by 11
A Proposed Algorithm for the Pharmacological Treatment of Generalized Anxiety Disorder in the Older Patient
Chen, A. C. N., Metzger, E. D., Lee, S., & Osser, D. N. (2024) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887241289533 · Cited by 16
CiPA-qualified human iPSC-derived cardiomyocytes: A new frontier in toxicity testing by evaluating drug-induced arrhythmias
Konala, V. B. R., Kuhikar, R., More, S., Goßmann, M., Lickiss, B., Linder, P., Sarkar, J., Bhanushali, P. B., & Khanna, A. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106100 · Cited by 9
Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk?
Mareti, Ε., Ampatzi, C., Paschou, S. Α., Voziki, E., & Goulis, D. G. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180911104942 · Cited by 8
The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study
Assimon, M. M., Pun, P. H., Al‐Khatib, S. M., Brookhart, M. A., Gaynes, B. N., Winkelmayer, W. C., & Flythe, J. E. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac214 · Cited by 8
Data-driven drug-induced QT prolongation surveillance using adverse reaction signals derived from 12-lead and continuous electrocardiogram data
Choi, B., Koo, Y., Kim, T. Y., Lim, H., & Yoon, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263117 · Cited by 8
QT prolongation and vortioxetine: a post-marketing study and comparison with other serotonin reuptake inhibitors
Bordet, C., Rousseau, V., Montastruc, F., & Montastruc, J. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05461-8 · Cited by 8
MENTAL DISORDERS AND CARDIOVASCULAR DISEASES: GUIDELINES OF THE BAIKAL PSYCHOSOMATIC ASSOCIATION AND THE SIBERIAN PSYCHOSOMATIC ASSOCIATION
Fi, B., Sumin, A. N., Garganeeva, N. P., Ларева, Н. В., Петрова, М. М., Петрунько, О. В., Попонина, Т. М., Repin, A. N., & Собенников, В. С. (2024) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2024-13-3s-222-253 · Cited by 8
The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients
Yasui‐Furukori, N., Tsuchimine, S., Kubo, K., Ishioka, M., Nakamura, K., & Inoue, Y. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000303 · Cited by 7
Antidepressants for major depression disorder in older people: a network meta-analysis
Robertson, L., Bertolini, F., Meader, N., Davies, S., Barbui, C., Gilbody, S. M., & Churchill, R. C. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013394 · Cited by 7
Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines
Buszewicz, M., Cape, J. D., Serfaty, M. A., Shafran, R., Kabir, T., Tyrer, P. J., Clarke, C. S., & Nazareth, I. (2017) · Health Technology Assessment · doi:10.3310/hta21450 · Cited by 8
Rise of escitalopram and the fall of citalopramPreprint
Cavanah, L. R., Ray, P. K., Goldhirsh, J. L., Huey, L. Y., & Piper, B. J. (2023) · medRxiv · doi:10.1101/2023.05.07.23289632 · Cited by 7
Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006–2018): A nationwide register‐based study
Elmowafi, H., Kindblom, J. M., Halldner, L., Gyllenberg, D., & Naumburg, E. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16321 · Cited by 9
Cardiovascular Disease and Bipolar Disorder: A Review of Pathophysiology and Treatment Implications
Chaudhari, M., Mendez, L., Olvera, R. L., Seshadri, S. S., & Teixeira, A. L. (2025) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174251316947 · Cited by 7
Divergent Phenotypes, Actionable Genotypes, and Phenoconversion in a German Psychiatric Inpatient Population: Results from the FACT-PGx Study
Eckert, A., Frantz, A. M., Scherf‐Clavel, M., Weber, H., Unterecker, S., Reif, A., & Hahn, M. (2024) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00042 · Cited by 6
Chemotherapy, Immunotherapy, and Psychotropic Use in Cancer Patients: A Review of Psychiatric Side Effects
Kurkjian, N., Tucker, P. M., Ostermeyer, B. K., & Valentine, A. D. (2017) · Psychiatric Annals · doi:10.3928/00485713-20170313-01 · Cited by 6
Safety of antidepressants commonly used in 6–17-year-old children and adolescents: A disproportionality analysis from 2014–2023 on the basis of the FAERS database
Zhou, Y., Lu, Y., Wu, Y., Kong, W., Zhou, L., Guo, X., Wei, H., Wang, H., Xie, F., Yan, S., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330025 · Cited by 8
Psychiatric Medications and Sudden Cardiac Death: Putting the Risk in Perspective
Howland, R. H. (2015) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20150122-01 · Cited by 5
Paroxetine‐induced QT c prolongation
Otsuka, Y. (2017) · Journal of General and Family Medicine · doi:10.1002/jgf2.137 · Cited by 5
The psychopharmacology of brain vascular disease/poststroke depression
Jones, M. B., Corcoran, A., & Jorge, R. E. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00013-7 · Cited by 5
Concurrent Serotonin Syndrome and Prolong QT Interval Induced by Paroxetine Overdose With Isotretinoin
Al-Radideh, O., Chan, K. H., Gupta, S., Slim, J., & Bellary, S. S. (2021) · Cureus · doi:10.7759/cureus.14497 · Cited by 5
Difference in patterns of prescribing antidepressants known for their weight-modulating and cardiovascular side effects for patients with obesity compared to patients with normal weight
Puzhko, S., Schuster, T., Barnett, T. A., Renoux, C., Munro, K., Barber, D., & Bartlett, G. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.018 · Cited by 5
Anxiety and psychological management of heart disease and heart surgery
Riordan, P., & Davis, M. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819814-8.00026-3 · Cited by 5
Rhythm and Blues
Koh, Y., Segan, L. A., Crowley, R. F., Das, S. K., Lim, M. W., Maizels, L., Davey, C. G., Voskoboinik, A., Kistler, P. M., Morton, J. B., et al. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.12.010 · Cited by 4
Improving Ambulatory Care Resident Training: Preparing for Opportunities to Treat Mental Illness in the Primary Care Setting
Farhat, N. M., Bostwick, J. R., & ROCKAFELLOW, S. D. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017729598 · Cited by 4
Self-citation
The relationship of cytochrome P450 isoforms with the efficacy and safety of antipsychotic and antidepressant therapy
Bairamova, S., Pavlova, O., Шпорт, С. В., Gurina, O. I., & Ka, P. (2023) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202312311140 · Cited by 4
Drug-drug-interactions in patients with atrial fibrillation admitted to the emergency department
Bischof, T., Nagele, F., Kalkofen, M. M., Blechschmidt, M. E. O., Domanovits, H., Zeitlinger, M. A., Schoergenhofer, C., & Cacioppo, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432713 · Cited by 4
AI-based integration of ECG biomarkers for assessing cardiac risk in type 2 diabetes mellitus with comorbid conditions for patient stratification
Savvopoulos, S., Hatzikirou, H., & Jelinek, H. F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1646495 · Cited by 3
Effects of exercise on psychological distress in patients with COPD: A systematic review and meta-analysis of randomised controlled trials
Liu, T., Ran, H., Xu, T., Xia, X., & Xia, J. (2025) · Medicine · doi:10.1097/md.0000000000044026 · Cited by 3
Citalopram and QT prolongation
Alusik, S., & Palúch, Z. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.174 · Cited by 3
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
Hwang, S., Lee, D. Y., Cho, J., Chung, J., Jang, I., Yu, K., & Lee, S. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s309763 · Cited by 3

Authors: Funk, K. A., & Bostwick, J. R.
Affiliations: University of Michigan (US)
ORCID: Funk, Kylee A.
Bostwick, Jolene R.
Venue: Annals of Pharmacotherapy
Publisher: SAGE Publications
Published: 2013-10
Volume: 47
Issue: 10
Pages: 1330-1341
ISSN: 0012-6578 (ISSN-L)
1060-0280
1542-6270
DOI: 10.1177/1060028013501994
OpenAlex: W2018099384
Cited by: 174
References: 52
Citations by year: 2026: 12 · 2025: 19 · 2024: 22 · 2023: 20 · 2022: 22 · 2021: 13 · 2020: 6 · 2019: 11 · 2018: 8 · 2017: 11 · 2016: 12 · 2015: 11 · 2014: 6
FWCI: 6.57
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Annals of Pharmacotherapy (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: QT prolongation, selective serotonin reuptake inhibitors, citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine, torsades de pointes, QTc interval, antidepressant safety, arrhythmia risk, acute coronary syndrome, FDA warning
MeSH terms: Antidepressive Agents, Humans, Long QT Syndrome, Risk, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Comparison of the Risk of QT Prolongation Among SSRIs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks